Literature DB >> 7688963

Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.

S Kondo1, M Asano, H Suzuki.   

Abstract

Angiogenesis is essential for successful tumor growth in vivo. There is a hypothesis that tumors secrete a putative tumor angiogenic factor (TAF) to facilitate blood vessel formations. Although several endothelial growth factors have been reported, it remains unclear whether these factors function as TAF in vivo. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) is a vascular endothelial mitogen that can increase blood vessel permeability. We have established a cell line (HeLa/v5), which secretes VEGF/VPF, by transfection of human VEGF/VPF cDNA. HeLa/v5 showed higher angiogenic activity, taken/planted ratio and tumor growth rate than the control transformant (HeLa/c), when they were implanted to nude mice. Administration of a polyclonal antibody, which neutralizes the mitogenic activity of VEGF/VPF in vitro, to the tumor implanted nude mice suppressed the in vivo growth of HeLa/v5. Furthermore, all 8 tumor cell lines we tested secrete VEGF/VPF into culture media. Our findings indicate that VEGF/VPF is a tumor angiogenic factor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688963     DOI: 10.1006/bbrc.1993.1955

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

Review 1.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis.

Authors:  S Yoshida; M Ono; T Shono; H Izumi; T Ishibashi; H Suzuki; M Kuwano
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

3.  Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro.

Authors:  A L Moreira; D R Friedlander; B Shif; G Kaplan; D Zagzag
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

Review 4.  Antiangiogenesis as a novel therapeutic concept in pediatric oncology.

Authors:  L Schweigerer
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

5.  [Anti-angiogenesis: a new approach to tumor therapy?].

Authors:  D Schiefer; C Gottstein; V Diehl; A Engert
Journal:  Med Klin (Munich)       Date:  1999-10-15

6.  Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.

Authors:  Nimer Assy; M Paizi; D Gaitini; Y Baruch; G Spira
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

7.  Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor.

Authors:  A J Pötgens; M C van Altena; N H Lubsen; D J Ruiter; R M de Waal
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Authors:  O Iliopoulos; A P Levy; C Jiang; W G Kaelin; M A Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 9.  Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Authors:  J P Crew; T S O'Brien; A L Harris
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

10.  Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro.

Authors:  Y Sawaji; T Sato; A Takeuchi; M Hirata; A Ito
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.